Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors

By on    Pharma Industry News  

Bristol-Myers Squibb partners with Compugen to trial COM701 and Opdivo combination for advanced solid tumors

Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with Compugen’s COM701 in the treatment of advanced solid tumors. This collaboration will evaluate the combination of COM701, an anti-PVRIG antibody under investigation by Compugen, with Opdivo, a programmed death-1 (PD-1) […]

Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors

By on    Pharma Industry News  

Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors

Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced solid tumors. This groundbreaking trial represents a significant advancement in the field of immuno-oncology, focusing on a novel immune checkpoint target identified through Compugen’s computational discovery capabilities. COM701 has been […]